Neuroinflammation in Alzheimer's Disease

Overview

Journal Lancet Neurol

Specialty Neurology

Date 2015 Mar 21

PMID 25792098

Citations 2605

Authors

Michael T Heneka

Monica J Carson

Joseph El Khoury

Gary E Landreth

Frederic Brosseron

Douglas L Feinstein

Andreas H Jacobs

Tony Wyss-Coray

Javier Vitorica

Richard M Ransohoff

Karl Herrup

Sally A Frautschy

Bente Finsen

Guy C Brown

Alexei Verkhratsky

Koji Yamanaka

Jari Koistinaho

Eicke Latz

Annett Halle

Gabor C Petzold

Terrence Town

Dave Morgan

Mari L Shinohara

V Hugh Perry

Clive Holmes

Nicolas G Bazan

David J Brooks

Stephane Hunot

Bertrand Joseph

Nikolaus Deigendesch

Olga Garaschuk

Erik Boddeke

Charles A Dinarello

John C Breitner

Greg M Cole

Douglas T Golenbock

Markus P Kummer

Affiliations

Soon will be listed here.

Abstract

Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release of inflammatory mediators, which contribute to disease progression and severity. Genome-wide analysis suggests that several genes that increase the risk for sporadic Alzheimer's disease encode factors that regulate glial clearance of misfolded proteins and the inflammatory reaction. External factors, including systemic inflammation and obesity, are likely to interfere with immunological processes of the brain and further promote disease progression. Modulation of risk factors and targeting of these immune mechanisms could lead to future therapeutic or preventive strategies for Alzheimer's disease.

Citing Articles

Do microglia metabolize fructose in Alzheimer's disease?.

Sturno A, Hassell Jr J, Lanaspa M, Bruce K J Neuroinflammation. 2025; 22(1):85.

PMID: 40089786 DOI: 10.1186/s12974-025-03401-x.

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.

Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.

PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.

Association between autoimmune disease and neurodevelopmental disorder: a Mendelian randomization analysis.

Qin J, Zhang Y, Hu R, Lin M, Yu R, Hua Y Ital J Pediatr. 2025; 51(1):76.

PMID: 40082977 PMC: 11905720. DOI: 10.1186/s13052-025-01910-2.

1, 4-benzodioxan-substituted Thienyl chalcone derivatives as novel reversible inhibitors of human monoamine oxidase B with anti-neuroinflammatory activity.

Sun D, Mu M, Jiang Y, Wang B, Kong Z, Tan J Sci Rep. 2025; 15(1):8690.

PMID: 40082573 PMC: 11906766. DOI: 10.1038/s41598-025-93076-4.

Could immunotherapy and regulatory T cells be used therapeutically to slow the progression of Alzheimer's disease?.

Abbott V, Housden B, Houldsworth A Brain Commun. 2025; 7(2):fcaf092.

PMID: 40078868 PMC: 11896979. DOI: 10.1093/braincomms/fcaf092.

References

van de Veerdonk F, Netea M, Dinarello C, Joosten L . Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol. 2011; 32(3):110-6. DOI: 10.1016/j.it.2011.01.003. View

Querfurth H, LaFerla F . Alzheimer's disease. N Engl J Med. 2010; 362(4):329-44. DOI: 10.1056/NEJMra0909142. View

Thiabaud G, Pizzocaro S, Garcia-Serres R, Latour J, Monzani E, Casella L . Heme binding induces dimerization and nitration of truncated β-amyloid peptide Aβ16 under oxidative stress. Angew Chem Int Ed Engl. 2013; 52(31):8041-4. DOI: 10.1002/anie.201302989. View

Sastre M, Dewachter I, Landreth G, Willson T, Klockgether T, Van Leuven F . Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003; 23(30):9796-804. PMC: 6740896. View

Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders A, Irizarry M . Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010; 30(2):131-46. PMC: 3214882. DOI: 10.1159/000318845. View

Kettenmann H, Hanisch U, Noda M, Verkhratsky A . Physiology of microglia. Physiol Rev. 2011; 91(2):461-553. DOI: 10.1152/physrev.00011.2010. View

Xia M, Qin S, Wu L, Mackay C, Hyman B . Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol. 1998; 153(1):31-7. PMC: 1852933. DOI: 10.1016/s0002-9440(10)65542-3. View

Rupprecht R, Papadopoulos V, Rammes G, Baghai T, Fan J, Akula N . Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010; 9(12):971-88. DOI: 10.1038/nrd3295. View

Olabarria M, Noristani H, Verkhratsky A, Rodriguez J . Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia. 2010; 58(7):831-8. DOI: 10.1002/glia.20967. View

10.

Brosseron F, Krauthausen M, Kummer M, Heneka M . Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol. 2014; 50(2):534-44. PMC: 4182618. DOI: 10.1007/s12035-014-8657-1. View

11.

Jekabsone A, Mander P, Tickler A, Sharpe M, Brown G . Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. J Neuroinflammation. 2006; 3:24. PMC: 1574293. DOI: 10.1186/1742-2094-3-24. View

12.

Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J . Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004; 10(7):719-26. DOI: 10.1038/nm1058. View

13.

Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov T . Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008; 64(10):835-41. DOI: 10.1016/j.biopsych.2008.04.021. View

14.

Jacobs A, Tavitian B . Noninvasive molecular imaging of neuroinflammation. J Cereb Blood Flow Metab. 2012; 32(7):1393-415. PMC: 3390799. DOI: 10.1038/jcbfm.2012.53. View

15.

Tan M, Yu J, Jiang T, Zhu X, Guan H, Tan L . IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice. J Alzheimers Dis. 2013; 38(3):633-46. DOI: 10.3233/JAD-131148. View

16.

Field R, Campion S, Warren C, Murray C, Cunningham C . Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010; 24(6):996-1007. PMC: 3334265. DOI: 10.1016/j.bbi.2010.04.004. View

17.

Lyketsos C, Breitner J, Green R, Martin B, Meinert C, Piantadosi S . Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007; 68(21):1800-8. DOI: 10.1212/01.wnl.0000260269.93245.d2. View

18.

Chidiac C . Pneumococcal infections and adult with risk factors. Med Mal Infect. 2012; 42(10):517-24. DOI: 10.1016/j.medmal.2012.04.003. View

19.

Strohmeyer R, Ramirez M, Cole G, Mueller K, Rogers J . Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J Neuroimmunol. 2002; 131(1-2):135-46. DOI: 10.1016/s0165-5728(02)00272-2. View

20.

Martin B, Szekely C, Brandt J, Piantadosi S, Breitner J, Craft S . Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol. 2008; 65(7):896-905. PMC: 2925195. DOI: 10.1001/archneur.2008.65.7.nct70006. View